Premium
Human papillomavirus infection in “young” versus “old” patients with squamous cell carcinoma of the head and neck
Author(s) -
Sisk Elizabeth A.,
Bradford Carol R.,
Jacob Abraham,
Yian Christopher H.,
Staton Kim M.,
Tang Gong,
Harris Monte O.,
Carey Thomas E.,
Lancaster Wayne D.,
Gregoire Lucie
Publication year - 2000
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/1097-0347(200010)22:7<649::aid-hed2>3.0.co;2-b
Subject(s) - human papillomavirus , medicine , polymerase chain reaction , southern blot , incidence (geometry) , hpv infection , head and neck cancer , oncology , head and neck , risk factor , cancer , pathology , cervical cancer , gene , biology , surgery , biochemistry , physics , optics
Background Human papillomavirus (HPV) represents a potential risk factor for squamous cell cancer of the head and neck (SCCHN). We evaluated the prevalence of HPV DNA in patients with SCCHN diagnosed at the University of Michigan from 1994–1996. Methods Patients were stratified by age at diagnosis as “young” (<50 years; median, 39) or “old” (>50 years; median, 66). Fourteen “young” and 14 “old” were matched for tumor site, and 4 additional “old” patients were included. Specimens were analyzed by polymerase chain reaction for HPV DNA using 2 sets of consensus primers. HPV sequences were confirmed by Southern blot hybridization and typed with type‐specific probes. Results Overall, 15 of 32 (46.9%) samples contained HPV sequences. HPV 16 was detected in 9 of 15 (60%), HPV‐18 in 1 of 15 (6.6%), and 5 of 15 (33.3%) remained untyped by multiple methods. When stratified, 7 of 14 (50%) “young” were HPV‐positive compared with 8 of 18 (44.4%) “old” ( p = .76). Survival in patients with HPV‐positive SCCHN was significantly longer than that for HPV‐negative patients. Conclusions The incidence of HPV in “young” versus “old” is not significantly different, suggesting similar roles for both groups. Patients with HPV‐positive tumors may have a survival advantage relative to patients with HPV‐negative tumors. © 2000 John Wiley & Sons, Inc. Head Neck 22: 649–657, 2000.